TY - JOUR
T1 - Stringent structural requirements for anti-Ras activity of S-prenyl analogues
AU - Aharonson, Ziporet
AU - Gana-Weisz, Mali
AU - Varsano, Tal
AU - Haklai, Roni
AU - Marciano, Daniele
AU - Kloog, Yoel
N1 - Funding Information:
This work was supported by a grant from the Israel Science Foundation (649/96-161) and in part by the Ehud and Lola Har-El Fund. We thank Dr. C. Weinberger for the gift of farnesol and farnesoic acid, and S. Smith for editorial assistance.
PY - 1998/2/27
Y1 - 1998/2/27
N2 - The carboxy terminal S-farnesylcysteine of Ras oncoproteins is required for their membrane anchorage and transforming activities. We showed previously that S-farnesylthiosalicylic acid (FTS) affects the membrane anchorage of activated H-Ras in EJ cells and inhibits their growth. We report here on structural elements in S-prenyl derivatives that specifically inhibit the growth of EJ cells, but not of untransformed Rat-1 cells. Inhibition of the Ras-dependent extracellular signal-regulated protein kinase (ERK), of DNA synthesis and of EJ cell growth were apparent after treatment with FTS or its 5-fluoro, 5-chloro and 4-fluoro derivatives or with the C20 S-geranylgeranyl derivative of thiosalicylic acid. The 4-Cl-FTS analogue was a weak inhibitor of EJ cell growth. The 3-Cl-FTS analogue and the FTS carboxyl methyl ester were inactive, as were the C10 S-geranyl derivative of thiosalicylic acid, farnesol, farnesoic acid, N-acetyl-S-farnesyl-L-cysteine and S-farnesylthiopropionic acid. The structural requirements for anti-Ras activity of S-prenyl analogues thus appear to be rather stringent. With regard to chain length, the C15 farnesyl group linked to a rigid backbone seems to be necessary and sufficient. A free carboxyl group in an appropriately rigid orientation as in thiosalicylic acid, is also required. Halogenic substituents on the benzene ring of the thiosalicylic acid are tolerated only at position 5 or 4. This information may facilitate the design of potent Ras antagonists and deepen our understanding of the mode of association of Ras with the plasma membrane.
AB - The carboxy terminal S-farnesylcysteine of Ras oncoproteins is required for their membrane anchorage and transforming activities. We showed previously that S-farnesylthiosalicylic acid (FTS) affects the membrane anchorage of activated H-Ras in EJ cells and inhibits their growth. We report here on structural elements in S-prenyl derivatives that specifically inhibit the growth of EJ cells, but not of untransformed Rat-1 cells. Inhibition of the Ras-dependent extracellular signal-regulated protein kinase (ERK), of DNA synthesis and of EJ cell growth were apparent after treatment with FTS or its 5-fluoro, 5-chloro and 4-fluoro derivatives or with the C20 S-geranylgeranyl derivative of thiosalicylic acid. The 4-Cl-FTS analogue was a weak inhibitor of EJ cell growth. The 3-Cl-FTS analogue and the FTS carboxyl methyl ester were inactive, as were the C10 S-geranyl derivative of thiosalicylic acid, farnesol, farnesoic acid, N-acetyl-S-farnesyl-L-cysteine and S-farnesylthiopropionic acid. The structural requirements for anti-Ras activity of S-prenyl analogues thus appear to be rather stringent. With regard to chain length, the C15 farnesyl group linked to a rigid backbone seems to be necessary and sufficient. A free carboxyl group in an appropriately rigid orientation as in thiosalicylic acid, is also required. Halogenic substituents on the benzene ring of the thiosalicylic acid are tolerated only at position 5 or 4. This information may facilitate the design of potent Ras antagonists and deepen our understanding of the mode of association of Ras with the plasma membrane.
KW - EJ cell line
KW - Farnesyl analog
KW - Geranylgeranyl analog
KW - Ras oncoproteins
KW - Ras-antagonists
UR - http://www.scopus.com/inward/record.url?scp=0032570931&partnerID=8YFLogxK
U2 - 10.1016/S0925-4439(97)00077-X
DO - 10.1016/S0925-4439(97)00077-X
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0032570931
VL - 1406
SP - 40
EP - 50
JO - Biochimica et Biophysica Acta - Molecular Basis of Disease
JF - Biochimica et Biophysica Acta - Molecular Basis of Disease
SN - 0925-4439
IS - 1
ER -